Tracking baby health: study follows pregnant women on rare disease drug
NCT ID NCT06312644
Summary
This study aims to gather information on the safety of the drug Ultomiris (ravulizumab) during pregnancy and breastfeeding. It will follow about 75 women who have rare conditions like PNH or aHUS and who took Ultomiris while pregnant. Researchers will track the health of both the mothers and their babies for up to one year after birth to look for any potential complications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGBoston, Massachusetts, 02210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Research Site
NOT_YET_RECRUITINGMelbourne, Victoria, 3050, Australia
Contact
-
Research Site
ACTIVE_NOT_RECRUITINGParis, 75475, France
-
Research Site
RECRUITINGEssen, Norte-Westfalia, D-45147, Germany
Contact
-
Research Site
ACTIVE_NOT_RECRUITINGRome, 00168, Italy
-
Research Site
ACTIVE_NOT_RECRUITINGSeoul, South Korea
-
Research Site
RECRUITINGSeoul, South Korea
Contact
-
Research Site
ACTIVE_NOT_RECRUITINGLondon, SE5 9NU, United Kingdom
Conditions
Explore the condition pages connected to this study.